Mefloquine anxiety, depression, unusual behavior, and suicidal ideations, among others. Neurologic effects include dizziness, loss of balance, and tinnitus. The label warns that mild symptoms may presage more serious ones, and that the drug should be discontinued at the first sign of symptoms. Mefloquine should not be used in people with a history of psychiatric problems. Central nervous system events requiring hospitalization occur in about one in 10,000 people taking mefloquine for malaria prevention, with milder events (e.g., dizziness, headache, insomnia, and vivid dreams) in up to 25%. When some measure of subjective severity is applied to the rating of adverse
International Association for the Treatment of Sexual Offenders (every single person's treatment and care is going to be different to what best fits that specific person). Every sex offender is different which is why their care and limits need to be properly customized for that individual in order to protect the people of the community and also to successfully prevent them from reoffending. The management of risk is an important part of treatment, but if there is only a limited focus on risk then it can lead to excessively confrontational therapeutic encounters, no close relationship between the offenders and clinicians (this can potentially make treatment unsuccessful because there